An anti-FGFR3 monoclonal antibody that inhibited not only wild-type FGFR3, but also various mutants of the receptor, exerted potent antitumor activity against bladder carcinoma and multiple myeloma xenografts in mice [78]. Here, FGFR3 is linked to AL amyloidosis.